News – Page 1072 – Endpoints News

The FDA still hates low T drugs — experts bat back a pair of contenders

8 years ago

Moderna expands pipeline to include liver disease programs; Imperial researchers team up with Heptares on ...

8 years ago

Truffle roots for new biotechs after first close of a planned $240M fund

8 years ago

Genentech adds a new program for Syndax’s lead cancer drug to its Tecentriq combo platform

8 years ago

Bluebird hopes for 3 drug approvals by 2019, including CAR-T and gene therapies

8 years ago

GSK’s long-quiet cancer R&D group is ready to make some noise as it mounts a breakout late-stage effort

8 years ago

The Endpoints 11: A group of disruptive upstarts on a do-or-die mission to launch new meds

8 years ago

Global Blood Therapeutics' sickle cell disease drug gets breakthrough therapy status; Boehringer Ingelheim will ...

8 years ago

Pfizer inks deal with startup Adapsyn to search microbes for novel compounds

8 years ago

Boasting a late-stage Botox me-too, Evolus files for $75M IPO

8 years ago

Billionaire-backed Juvenescence primes the anti-aging pipeline pump with a $12M seed round

8 years ago

Axovant: That positive p-value we reported yesterday? Um, we screwed that up too

8 years ago

On a mission to save Teva from crippling debt, Schultz stands by cost-cutting measures, scrutinizes per product ...

8 years ago

After bumpy 2017, Celgene CEO says taking risk is the only way forward

8 years ago

Shire creates separate neurosciences division for future investments; Agenus gains $28M in royalty deal

8 years ago

Sanofi, Regeneron up the ante on PD-1 I/O program by a billion dollars

8 years ago

Teva inks $200M global licensing deal with migraine rival Alder

8 years ago

Axovant shares blasted as Vivek Ramaswamy's premier drug proves worthless, second drug misses key goal

8 years ago

Novo Nordisk tries to tackle Ablynx and bring it into the fold with a $3B buyout offer, but the biotech keeps saying ...

8 years ago

Alnylam kicks off #JPM18 with a restructured Sanofi deal, grabbing global rights to patisiran

8 years ago

Developing a Sanofi cast-off, Impact Biomedicines now subject of $7B Celgene acquisition deal

8 years ago

Pfizer is axing its neurosciences division, laying off 300 and discarding new drugs

8 years ago

After resisting a push to the auction block, Acorda preps for a sale and shares shoot up — report

8 years ago

J&J does Alzheimer's gene therapy deal, along with 14 other new collaborations

8 years ago

First page Previous page 1069 1070 107110721073 1074 1075 Next page Last page